Zylembio
1 known investors
Zylem Biosciences develops Metabolic Redox Modulators (MRMs), a patented platform of drug candidates targeting the SR-B1 receptor to treat cancer, cardiovascular disease, and other age-related conditions. The company leverages fifteen years of research from Northwestern University to create therapeutics that induce metabolic dysfunction in disease cells while sparing healthy cells.
Founders & leadership
ST
Shad ThaxtonMD, PhD
KM
Kaylin McMahonPhD
PB
Philip Bligh
Board
JV
Jay VenkatesanMD, MBA
LG
Leo GordonMD
Investors · 1
Frequently asked questions
- What does Zylembio do?
- Zylem Biosciences develops Metabolic Redox Modulators (MRMs), a patented platform of drug candidates targeting the SR-B1 receptor to treat cancer, cardiovascular disease, and other age-related conditions. The company leverages fifteen years of research from Northwestern University to create therapeutics that induce metabolic dysfunction in disease cells while sparing healthy cells.
- Who founded Zylembio?
- Zylembio was founded by Shad Thaxton.
- Who are Zylembio's investors?
- Zylembio's investors include Portal Innovations.